These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 19212639

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J, Couture F, Young S, McWatters KL, Lau CY.
    J Clin Oncol; 2005 Apr 20; 23(12):2597-605. PubMed ID: 15452188
    [Abstract] [Full Text] [Related]

  • 3. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun 20; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.
    Tsuboi M, Ezaki K, Tobinai K, Ohashi Y, Saijo N.
    Jpn J Clin Oncol; 2009 Mar 20; 39(3):163-8. PubMed ID: 19164318
    [Abstract] [Full Text] [Related]

  • 10. Side-effects of pre-operative epirubicin-paclitaxel therapy in primary breast cancer associated with tumor biology.
    Warm M, Kates R, Thomas A, Fischer T, Harbeck N.
    Anticancer Res; 2009 Jul 20; 29(7):2675-80. PubMed ID: 19596945
    [Abstract] [Full Text] [Related]

  • 11. Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study.
    Rades D, Tribius S, Yekebas EF, Bahrehmand R, Wildfang I, Kilic E, Muellerleile U, Gross E, Schild SE, Alberti W.
    Int J Radiat Oncol Biol Phys; 2006 Jun 01; 65(2):459-65. PubMed ID: 16584851
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer.
    Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C.
    J Clin Oncol; 2009 Dec 01; 27(34):5751-6. PubMed ID: 19884550
    [Abstract] [Full Text] [Related]

  • 16. Effects of epoetin-alpha on quality of life of cancer patients with solid tumors receiving chemotherapy.
    Christodoulou C, Dafni U, Aravantinos G, Koutras A, Samantas E, Karina M, Janinis J, Papakostas P, Skarlos D, Kalofonos HP, Fountzilas G.
    Anticancer Res; 2009 Feb 01; 29(2):693-702. PubMed ID: 19331224
    [Abstract] [Full Text] [Related]

  • 17. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
    Borg S, Glenngård AH, Osterborg A, Persson U.
    Acta Oncol; 2008 Feb 01; 47(6):1009-17. PubMed ID: 18770060
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.
    Suzuki Y, Tokuda Y, Fujiwara Y, Minami H, Ohashi Y, Saijo N.
    Jpn J Clin Oncol; 2008 Mar 01; 38(3):214-21. PubMed ID: 18296425
    [Abstract] [Full Text] [Related]

  • 20. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.
    Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR.
    J Clin Oncol; 2006 Aug 01; 24(22):3583-9. PubMed ID: 16877725
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.